Risultati per: Ipotesi sull’origine di Omicron e sua evoluzione

Annals of Internal Medicine, Volume 175, Issue 10, Page W119, October 2022.

I ricercatori stanno monitorando le varianti che potranno essere responsabili di una nuova ondata di Sars-CoV2 nella stagione invernale

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Volume 175, Issue 12, Page 1693-1706, December 2022.

Annals of Internal Medicine, Volume 175, Issue 12, Page 1685-1692, December 2022.

To the Editor We have some concerns about the recent Research Letter that investigated the risk of infection and hospitalization among vaccinated and unvaccinated children and adolescents after the emergence of the SARS-CoV-2 Omicron variant.

In Reply Drs Hsu and Lai raise some important points regarding our Research Letter that aimed to provide timely results that could inform public health practice, drawing on readily available surveillance data. Our principal finding brought attention to waning vaccine efficacy in children aged 5 to 11 years during the Omicron surge. Since its publication, several other studies have replicated our study’s main conclusions.

New England Journal of Medicine, Ahead of Print.

This retrospective study compares the severity of SARS-CoV-2 infection among persons infected with BA.1 and BA.2 sublineages by vaccination status.

Unsupervised SARS-CoV-2 rapid antigen testing with three commercial kits had 70% to 81% sensitivity during the period when Omicron emerged and became predominant in the Netherlands.

Chi vuole ricevere la quarta dose, anche tra gli under 60, lo potrà fare prenotando la somministrazione all’hub oppure alla farmacia o dal medico di famiglia

Dopo quelli per Omicron 1 al via anche i vaccini per Omicron 4-5, le sottovarianti al momento prevalenti in Italia. In arrivo da lunedì 6 milioni di dosi

Objectives
While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries (LICs) has received a full primary vaccine series, compared with over 70% of the population of high-income nations.

Design
We used economic and epidemiological models, parameterised with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programmes in LICs and lower-middle-income countries (LMICs) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2.

Setting
Low-income and lower-middle-income nations.

Main outcome measures
Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs.

Findings
Globally, universal vaccination in LIC/LMIC with three doses of an mRNA vaccine would result in an estimated 1.5 million COVID-19 deaths averted with a total estimated cost of US$61 billion and an estimated cost-per-COVID-19 death averted of US$40 800 (sensitivity analysis range: US$7400–US$81 500). Lower estimated infection fatality ratios, higher cost-per-dose and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis.

Conclusions
Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life. Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.

Annals of Internal Medicine, Ahead of Print.